{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T00:45:08Z","timestamp":1778546708447,"version":"3.51.4"},"reference-count":17,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2014,3,11]],"date-time":"2014-03-11T00:00:00Z","timestamp":1394496000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Adv Ther"],"published-print":{"date-parts":[[2014,4]]},"DOI":"10.1007\/s12325-014-0109-9","type":"journal-article","created":{"date-parts":[[2014,3,10]],"date-time":"2014-03-10T04:36:14Z","timestamp":1394426174000},"page":"461-471","source":"Crossref","is-referenced-by-count":11,"title":["Prospective Observational Post-Marketing Study of Tafluprost for Glaucoma and Ocular Hypertension: Short-Term Efficacy and Safety"],"prefix":"10.1007","volume":"31","author":[{"given":"Yasuaki","family":"Kuwayama","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akio","family":"Nomura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2014,3,11]]},"reference":[{"key":"109_CR1","doi-asserted-by":"crossref","first-page":"1268","DOI":"10.1001\/archopht.120.10.1268","volume":"120","author":"A Heijl","year":"2002","unstructured":"Heijl A, Leske MC, Bengtsson B, et al. Reduction of intraocular pressure and glaucoma progression: results from the early manifest glaucoma trial. Arch Ophthalmol. 2002;120:1268\u201379.","journal-title":"Arch Ophthalmol"},{"key":"109_CR2","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1016\/S0002-9394(00)00538-9","volume":"130","author":"The AGIS investigators","year":"2000","unstructured":"The AGIS investigators. The advanced glaucoma intervention study (AGIS): 7. The relationship between control of intraocular pressure and visual field deterioration. Am J Ophthalmol. 2000;130:429\u201340.","journal-title":"Am J Ophthalmol"},{"key":"109_CR3","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1016\/S0002-9394(98)00223-2","volume":"126","author":"Collaborative Normal-Tension Glaucoma Study Group","year":"1998","unstructured":"Collaborative Normal-Tension Glaucoma Study Group. Comparison of glaucomatous progression between untreated patients with normal-tension glaucoma and patients with therapeutically reduced intraocular pressures. Am J Ophthalmol. 1998;126:487\u201397.","journal-title":"Am J Ophthalmol"},{"key":"109_CR4","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1001\/archopht.121.1.48","volume":"121","author":"MC Leske","year":"2003","unstructured":"Leske MC, Heijl A, Hussein M, et al. Factors for glaucoma progression and the effect of treatment: the early manifest glaucoma treatment trial. Arch Ophthalmol. 2003;121:48\u201356.","journal-title":"Arch Ophthalmol"},{"key":"109_CR5","doi-asserted-by":"crossref","first-page":"1","DOI":"10.2165\/00002512-200522010-00001","volume":"22","author":"RE Marquis","year":"2005","unstructured":"Marquis RE, Whitson JT. Management of glaucoma: focus on pharmacological therapy. Drugs Aging. 2005;22:1\u201321.","journal-title":"Drugs Aging"},{"key":"109_CR6","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1016\/j.exer.2003.12.007","volume":"78","author":"Y Takagi","year":"2004","unstructured":"Takagi Y, Nakajima T, Shimazaki A, et al. Pharmacological characteristics of AFP-168 (tafluprost), a new prostanoid FP receptor agonist, as an ocular hypotensive drug. Exp Eye Res. 2004;78:767\u201376.","journal-title":"Exp Eye Res"},{"key":"109_CR7","doi-asserted-by":"crossref","first-page":"163","DOI":"10.2147\/OPTH.S6368","volume":"4","author":"M Aihara","year":"2010","unstructured":"Aihara M. Clinical appraisal of tafluprost in the reduction of elevated intraocular pressure (IOP) in open-angle glaucoma and ocular hypertension. Clin Ophthalmol. 2010;4:163\u201370.","journal-title":"Clin Ophthalmol"},{"key":"109_CR8","first-page":"1641","volume":"111","author":"A Iwase","year":"2004","unstructured":"Iwase A, Suzuki Y, Araie M, et al. The prevalence of primary open-angle glaucoma in Japanese: the Tajimi Study. Ophthalmology. 2004;111:1641\u20138.","journal-title":"Ophthalmology"},{"key":"109_CR9","doi-asserted-by":"crossref","first-page":"1661","DOI":"10.1016\/j.ophtha.2005.05.012","volume":"112","author":"T Yamamoto","year":"2005","unstructured":"Yamamoto T, Iwase A, Araie M, et al. The Tajimi Study report 2: prevalence of primary angle closure and secondary glaucoma in a Japanese population. Ophthalmology. 2005;112:1661\u20139.","journal-title":"Ophthalmology"},{"key":"109_CR10","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1007\/s10384-005-0293-x","volume":"50","author":"Y Ikeda","year":"2006","unstructured":"Ikeda Y, Mori K, Ishibashi T, Naruse S, Nakajima N, Kinoshita S. Latanoprost nonresponders with open-angle glaucoma in the Japanese population. Jpn J Ophthalmol. 2006;50:153\u20137.","journal-title":"Jpn J Ophthalmol"},{"key":"109_CR11","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1097\/00061198-200312000-00004","volume":"12","author":"CB Camras","year":"2003","unstructured":"Camras CB, Hedman K, US Latanoprost Study Group. Rate of response to latanoprost or timolol in patients with ocular hypertension or glaucoma. J Glaucoma. 2003;12:466\u20139.","journal-title":"J Glaucoma"},{"key":"109_CR12","doi-asserted-by":"crossref","first-page":"1579","DOI":"10.2147\/OPTH.S33414","volume":"6","author":"T Mizoguchi","year":"2012","unstructured":"Mizoguchi T, Ozaki M, Unoki K, Dake Y, Eto T, Arai M. A randomized crossover study comparing tafluprost 0.005% with travoprost 0.004% in patients with normal-tension glaucoma. Clin Ophthalmol. 2012;6:1579\u201384.","journal-title":"Clin Ophthalmol"},{"key":"109_CR13","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1007\/s10384-012-0155-2","volume":"56","author":"I Kawaguchi","year":"2012","unstructured":"Kawaguchi I, Higashide T, Ohkubo S, Kawaguchi C, Sugiyama K. Comparison of efficacy of four prostaglandin analogues by bilateral treatment in healthy subjects. Jpn J Ophthalmol. 2012;56:346\u201353.","journal-title":"Jpn J Ophthalmol"},{"key":"109_CR14","first-page":"123","volume":"21","author":"H Kurashima","year":"2012","unstructured":"Kurashima H, Asai Y, Aihara M, Ishida N, Nakamura M, Araie M. Ocular hypotensive effect of tafluprost in latanoprost low-responder cynomolgus monkeys. J Glaucoma. 2012;21:123\u20138.","journal-title":"J Glaucoma"},{"key":"109_CR15","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1007\/s10384-011-0082-7","volume":"55","author":"T Nakano","year":"2011","unstructured":"Nakano T, Yoshikawa K, Kimura T, Suzumura H, Nanno M, Noro T. Efficacy and safety of tafluprost in normal-tension glaucoma with intraocular pressure of 16\u00a0mmHg or less. Jpn J Ophthalmol. 2011;55:605\u201313.","journal-title":"Jpn J Ophthalmol"},{"key":"109_CR16","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1111\/j.1755-3768.2010.01862.x","volume":"88","author":"H Uusitalo","year":"2010","unstructured":"Uusitalo H, Pillunat LE, Ropo A. Efficacy and safety of tafluprost 0.0015% versus latanoprost 0.005% eye drops in open-angle glaucoma and ocular hypertension: 24-month results of a randomized, double-masked Phase III study. Acta Ophthalmol. 2010;88:12\u20139.","journal-title":"Acta Ophthalmol"},{"key":"109_CR17","doi-asserted-by":"crossref","first-page":"1459","DOI":"10.2147\/OPTH.S13720","volume":"8","author":"D Schnober","year":"2010","unstructured":"Schnober D, Hofmann G, Maier H, Scherzer ML, Ogundele AB, Jasek MC. Diurnal IOP-lowering efficacy and safety of travoprost 0.004% compared with tafluprost 0.0015% in patients with primary open-angle glaucoma or ocular hypertension. Clin Ophthalmol. 2010;8:1459\u201363.","journal-title":"Clin Ophthalmol"}],"container-title":["Advances in Therapy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-014-0109-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s12325-014-0109-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-014-0109-9","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,6,2]],"date-time":"2019-06-02T03:56:05Z","timestamp":1559447765000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s12325-014-0109-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,3,11]]},"references-count":17,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2014,4]]}},"alternative-id":["109"],"URL":"https:\/\/doi.org\/10.1007\/s12325-014-0109-9","relation":{},"ISSN":["0741-238X","1865-8652"],"issn-type":[{"value":"0741-238X","type":"print"},{"value":"1865-8652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,3,11]]}}}